Coronary Heart Disease, Percutaneous Coronary Intervention
Conditions
Brief summary
The DigiCare-CHD study is an investigator-initiated, multicenter, open-label, parallel-group randomized controlled trial. It aims to evaluated the efficacy of a smartphone-based digital remote management platform compared to usual care in achieving dual goal attainment of blood pressure and LDL-cholesterol levels in patients with coronary heart disease following percutaneous coronary intervention.
Detailed description
Coronary heart disease (CHD) remains a leading cause of global mortality. While percutaneous coronary intervention (PCI) significantly improves acute survival, patients continue to face substantial residual cardiovascular risk driven by the progression of systemic atherosclerosis. Rigorous management of blood pressure (BP) and low-density lipoprotein cholesterol (LDL-C) is imperative for secondary prevention. However, achieving simultaneous targets (BP \< 130/80 mmHg and LDL-C \< 1.4 mmol/L) in real-world practice is challenging due to clinical inertia and suboptimal patient adherence. Traditional outpatient follow-up is often fragmented and reactive, failing to provide the continuous monitoring required for optimal risk factor control. The DigiCare-CHD trial serves as a prospective, multicenter, open-label randomized controlled trial designed to enroll 792 patients who have successfully undergone PCI for acute or chronic coronary syndromes. Participants will be randomized 1:1 to either the Digital Remote Management group or the Usual Care group, with a follow-up period of 12 months. Patients in the intervention arm will utilize a digital remote management platform. This system integrates home monitoring to track BP, lipid profiles, and physical activity. Key features include AI-driven alerts for abnormal values, automated decision support for medication titration (verified by physicians), and targeted health education. The primary endpoint is the rate of dual goal attainment for BP and LDL-C at 12 months. DigiCare-CHD aims to establish a proactive, closed-loop management strategy to effectively reduce residual cardiovascular risk and improve long-term prognosis in the post-PCI population.
Interventions
1-year intervention 1. BP Management: Protocol-driven self-monitoring frequencies. The system triggers alerts for BP \>130/80 mmHg and generates automated suggestions for medication titration, subject to physician approval. 2. Lipid Management: Automated reminders for laboratory testing. Optical Character Recognition (OCR) technology extracts data from lab reports. If LDL-C ≥1.4 mmol/L, the system proposes regimen intensification for physician review. 3. Exercise Management:Target of ≥6000 steps/day. Data is synchronized via wearables or smartphones. Inactivity triggers automated behavioral feedback. 4. Medication Management: Daily app-based reminders and digital check-ins. Non-adherence triggers automated alerts followed by human intervention if persistent. 5. Symptom Monitoring: Patient-reported outcomes (e.g., chest pain/dyspnea) via the App, with automated triage for risk stratification. 6. Health Education: Push delivery of targeted secondary prevention educational materials.
Sponsors
Beijing Anzhen Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Age 18-75 years 2. Diagnosis of Acute Coronary Syndrome (ACS) or Chronic Coronary Syndrome (CCS) 3. Status post-successful percutaneous coronary intervention (PCI). 4. Possession of a smartphone and ability to operate the application (independently or with caregiver assistance). 5. Provision of written informed consent.
Exclusion criteria
1. Heart Failure: NYHA Class III-IV or LVEF \< 40%. 2. Severe hepatic dysfunction (ALT/AST ≥3xULN or Total Bilirubin \>1.5 mg/dl) 3. Severe renal dysfunction (eGFR \< 30 ml/min/1.73m² or requiring dialysis) 4. Uncontrolled hypothyroidism (TSH \>1.5xULN or \>10 mIU/L, or unstable dosage within 6 weeks) 5. Life expectancy \< 1 year due to non-cardiovascular comorbidities 6. Severe sensory (hearing/vision) or cognitive impairment precluding device use 7. Conditions affecting adherence (e.g., substance use disorder, history of alcohol abuse)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Rate of Dual Goal Attainment for Blood Pressure and Lipids | 12 months after randomization | Defined as the proportion of patients achieving both SBP \< 130 mmHg and DBP \< 80 mmHg and LDL-C \< 1.4 mmol/L. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Exercise Compliance Rate | 12 Months | Proportion of patients maintaining an average of ≥6000 steps/day. |
| Medication Adherence | 12 Months | MARS-10 scale |
| Change in Left Ventricular Ejection Fraction (LVEF) | Baseline and 12 Months | — |
| Quality of Life（EQ-5D-5L） | 12 Months | EQ-5D-5L |
| Major Adverse Cardiovascular Events (MACE) Composite of all-cause death, myocardial infarction, malignant arrhythmia, or hospitalization for heart failure. | 12 Months | — |
| Smoking Cessation Rate | 12 Months | Self-reported complete abstinence from smoking among baseline smokers |
Countries
China
Contacts
Primary ContactDigiCare-CHD Coordinating Center
Outcome results
None listed